| Background and objective:Lung cancer was one the most commonly diagnosed cancer as well as the leading cause of cancer death in China. The aim of this study is to assess the efficacy and adverse reactions of bronchial artery infusion and intravenous chemotherapy for treating advanced non-small cell lung cancer. Methods:By searching PubMed, Cochranelibrary, SinoMed, China National Knowledge Internet and Wanfang Database, we collected both domestic and overseas published literatures between 2000 and 2014 on clinical control trial of bronchial artery infusion versus intravenous chemotherapy for treating advanced non-small cell lung cancer. These literatures were strictly selected and the quality of selected literatures were assessed based on methodological index for non-randomized studies. Then we used the RevMan 5.0 software for meta-analysis. Results:Eleven eligible literatures were included. The effective rate in bronchial artery infusion group is significantly higher than intravenous chemotherapy group(RR,1.57; 95%CI,1.37-1.82; PO.001; 12=0%), but no difference was observed in one-year survival rate(RR,1.57; 95%CI,1.37-1.82; P<0.001; 12=0%). In the trials with data on adverse reactions, bronchial artery infusion was associated with a significantly lower incidence of thrombocytopenia 9RR,0.77; 95%CI,0.56-1.04; P=0.09; 12=87%), but there are no statistical differences in the incidence of leucopenia (RR,0.77; 95%CI,0.56-1.04; P=0.09; 12=87%)and nausea/vomiting(RR,0.64; 95%CI,0.30-1.37; P=0.25; 12=98%). Conclusion:Bronchial Artery Infusion is more effective than intravenous chemotherapy for treating advanced non-small cell lung cancer, and it can also reduce some adverse reactions of chemotherapy. |
PDF Full Text Request